VCYT Q3 2019 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+32.0% YoY

Gross Profit

$22M70.6% margin

Operating Income

-$2M-5.7% margin

Net Income

-$730,000-2.4% margin

EPS (Diluted)

$-0.01

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$260M

Total Liabilities

$29M

Stockholders' Equity

$231M

Cash & Equivalents

$196M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$23M	+32.0%
Gross Profit	$22M	$15M	+43.8%
Operating Income	-$2M	-$4M	+59.0%
Net Income	-$730,000	-$4M	+83.7%

Revenue Segments

Service

$250,00074%

Product

$90,00026%